У нас вы можете посмотреть бесплатно Part 4 LIPAGLYN MASLD PRO 2025 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
This will be the concluding lecture in this series If not done already, please also sign up on our Technocrinology.com platform to get access to all the previous lectures, notes on the current lectures, and tools and applications: https://technocrinology.thinkific.com... Summary Introduction & Treatment Principles (14:13-18:02) Final part of a four-part series on MSLD Overview of comprehensive management approach Targets for treatment: patients with steatohepatitis, F2-F3 fibrosis, and comorbidities All patients should receive lifestyle modification and comorbidity management Lifestyle Modifications (18:02-27:00) Weight loss goals: 7-10% reduction reverses steatohepatitis Correlation between weight loss percentage and MSLD improvement Dietary approaches: Mediterranean diet, low-carb, intermittent fasting Patient monitoring recommendations using fibroscan and FIB4 index Follow-up frequency based on risk stratification Approved Medications for MSLD (27:00-38:52) Resmetirom: TR-beta thyroid receptor agonist (US FDA approved) MAESTRO trial results showing nash resolution and fibrosis improvement Saroglitazar: dual PPARα/γ agonist (Indian DCGI approved) Evidence from phase 2/3 trials for saroglitazar Both drugs demonstrate reduction in liver fat, inflammation, and fibrosis Repurposed Medications for MSLD (38:52-54:18) SGLT2 inhibitors: benefits beyond weight loss GLP-1 receptor agonists: tirzepatide showing fibrosis improvements Pioglitazone: benefits in diabetic MSLD patients Thyroid hormone T3 considerations in hypothyroid patients Mechanism of intrahepatic hypothyroidism in MSLD Additional Therapeutic Options (54:18-end) Bariatric surgery: 88% improvement in steatosis, 30% in fibrosis Emerging therapies: FGF21 agonists showing promise UDCA: controversial benefits, mainly symptomatic improvement Vitamin E: effective in non-diabetic MSLD (PIVENS trial) Practical approach to selecting therapy based on patient characteristics